Abstract
Biodegradable cellular carrier has desired properties for achieving effective long-term controlled release of drugs having short half life. To reduce the undesired effects of drug, advanced drug delivery systems are needed which are based on specific cell targeting module. Artesunate (ART) conjugation on nanoerythrosomes (NE) can have controlled delivery to avoid drug leakage, increase the stability, and reduce cost and toxicities. In this study nanosized lipoprotein membrane vesicles bearing ART were prepared by extrusion method. Developed ART-NE conjugate formulations were optimized on the basis of vesicle morphology, size and size distribution, polydispersity index, integrity of membrane, loaded drug concentration, drug leakage, effect of temperature and viscosity, syringeability, in vitro release profile and in vivo plasma concentration estimation studies. Fourier transform infrared (FTIR) spectroscopy reveals that lipid chain order of RBCs are insignificantly affected in moderate conditions after ART loading. The formulated ART-NE carrier revealed non aggregated, uniformly sized particles with smooth surfaces. The maximum drug loading was found to be 25.20 ± 1.3 μg/ml. ART-NE formulation was best fit for zero order kinetics and was found to be capable of controlled release of drug for 8 hrs. ART-NE formulation showed good redispersibility with desirable properties for parenteral administration. Formulation was stable when subjected to stress by centrifugal force of 7500 rpm and could bear turbulence shock of 15 passes from hypodermic needle of size 23 gauges. The ART-NE formulation administered intravenously showed higher plasma concentration compared to free drug signifying not only controlled release but higher rate of in vivo release. The developed formulation exhibited zero order release profile as per kinetic study analysis suggesting the suitability of carrier for the sustained and targeted delivery of ART. The developed ART-NE drug delivery system offers improved pharmacokinetic profile with assurance of increased therapeutic efficacy.
Similar content being viewed by others
References
Anvikar AR, Arora U, Sonal GS, Mishra N, Shahi B, Savargaonkar D, et al. Anti malarial drug policy in India: Past, present and future. Ind J Med Res. 2014;139(2):205–15.
Xiao XC, Hon Z. Firstborn microcrystallization method to prepare nanocapsules containing Artesunate. Int J Nanomedicine. 2010;5:483–6.
White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41:1413–22.
Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther. 1991;50(1):95–121.
White NJ. Artemisinin: current status. Trans R Soc Trop Med Hyg. 1994;88:S3–4.
Meng H, Xu K, Xu Y, Luo P, Du F, Huang J, et al. Nanocapsules based on mPEGylated artesunate prodrug and its cytotoxicity. Colloid Surf B. 2014;115:164–9.
Agnihotri J, Singh S, Bigonia P. Formal chemical stability analysis and solubility analysis of artesunate and hydroxychloroquinine for development of parenteral dosage form. J Pharm Res. 2013;6(1):117–22.
Chadha R, Gupta S, Pathak N. Artesunate-loaded chitosan/lecithin nanoparticles: preparation, characterization, and in vivo studies. Drug Dev Ind Pharm. 2012;38(12):1538–46.
Nguyen DT, Tran TH, Kim JO, Yong CS, Nguyen CN. Enhancing the in vitro anti-cancer efficacy of artesunate by loading into polyd, l-lactide-co-glycolide (PLGA) nanoparticles. Arch Pharm Res. 2015;38(5):716–24.
Batty KT, Ilett KF, Davis ME. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol. 1996;48(1):22–6.
Tiwari G, Tiwari R, Srivastava B, Bhati L, Pandey P, Bannerjee S. Drug delivery systems: An updated review. Int J Pharm Investig. 2012;2(1):2–11.
Muzykantov VR, Smirnov MD, Klibanov AL. Avidin attachment to biotinylated amino groups of the erythrocyte membrane eliminates homologous restriction of both classical and alternative pathways of the complement. FEBS Lett. 1993;318(2):108–12.
Muzykantov VR, Seregina N, Smirnov MD. Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes. Int J Artif Organs. 1992;15:622–7.
Shi J, Kundrat L, Pishesha N, Bilate A, Theile C, Maruvama T, et al. Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. Proc Natl Acad Sci U S A. 2014;111(28):10131–6.
Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Povet P, Gaudreault R. Nanoerythrosomes, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 1994;14(3A):915–9.
Gaudreault RC, Gicquaud C, Poyet P. Nanoerythrosome as bioactive agent carrier. 1997;US patent 5653999
Lanao JM, Sayalero ML. Cells and Cell Ghosts as Drug Carriers. In: Torchilin VP, editor. Nanoparticulates as Drug Carriers. London: World Scientific, Imperial College Press; 2006. p. 329–48.
Jain S, Jain NK. Engineered erythrocytes as a drug delivery system. Ind J Pharm Sci. 1997;59(6):275–81.
Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Povet P, Gaudreault R. Nanoerythrosomes, a new derivative of erythrocyte ghost II:Identification of the mechanism of action. Anticancer Res. 1996;16(5A):2831–6.
DeLoach RE, Droleskey K, Andrews K. Encapsulation by hypotonic dialysis in human erythrocytes: a diffusion or endocytosis process. Biotechnol Appl Biochem. 1991;13(1):72–82.
Agnihotri J, Jain NK, Gajbhiye V. Engineered cellular carrier nanoerythrosomes as potential targeting vectors for anti-malarial drug. Asian J Pharmaceutics. 2010;4(2):116–20.
Bellemare F, Gaudreault R. Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof. 1998;Patent WO1998011919 A2.
Agnihotri J, Jain NK. Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine, Artificial Cells, Nanomedicine, and Biotechnology. 2013;41(5):309–14.
Gabriels M, Plaizier-Vercammen J. Physical and chemical evaluation of liposomes containing artesunate. J Pharm Biomed Anal. 2003;31(4):655–67.
Seguro AC, Campos SB. Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg. 2002;67:473–4.
Merkus HG. Particle Size, Size Distribution and Shape. In: Particle Size Measurements: Fundamentals, Practice, Quality. Netherlands: Springer; 2009. p. 13 − 42
Particle size, Particle size distributions from sub-nanometer to millimetres. www.malvern.com. Available at: http://www.malvern.com/en/products/measurement-type/particle-size/default.aspx. Accessed on: 12th Dec. 2014.
Patravale V, Dandekar P, Jain R. Nanoparticulate Drug Delivery: Perspectives on the Transition from Laboratory to Market. In: Nanoparticulate Drug Delivery. 1st edition. UK: Woodhead Publishing Ltd; 2012. p. 65–7.
Liberman HA, Martin MR, Banker GS. Pharmaceutical Dosage forms Dispersed systems. Vol 2. New York: Marcel Dekker; 1996. p. 285.
Avis KE, Lachman L. Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese publishing; 1976. p. 654.
Nash RA. Formulation of pharmaceutical suspension. Part I. Drug and Cosmetic Industry. 1965;97:843.
Acknowledgments
The authors are thankful to Prof. Vandana B Patrawala, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, and lab staff for their invaluable help in handling and operating of the instruments in their laboratory for this research work.
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agnihotri, J., Saraf, S., Singh, S. et al. Development and evaluation of anti-malarial bio-conjugates: artesunate-loaded nanoerythrosomes. Drug Deliv. and Transl. Res. 5, 489–497 (2015). https://doi.org/10.1007/s13346-015-0246-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-015-0246-y